BDMAI/CSIR-NCL/2026 27th October 2026

Dr. Amol A. Kulkarni
Chief Scientist & Head, Chemical Engineering & Process Development Division,
CSIR-National Chemical Laboratory
Dr. Homi Bhabha Road, Pashan
Pune – 411008, India

Dear Sir,

Sub: ANRF–Translational Research and Innovation (ATRI) Centre – Expression of Interest and Request for Establishment of a Pilot Plant at Hyderabad

Greetings from the Bulk Drug Manufacturers Association of India (BDMAI).

This has reference to your email dated 27 October 2026 and the subsequent telephonic discussion with our former President, Mr. R. K. Agrawal, regarding the above subject. We are pleased to learn that the proposal jointly submitted by CSIR-NCL, Pune, and ICT, Mumbai, for establishing an ANRF–Translational Research and Innovation (ATRI) Centre has been shortlisted.

It has long been our aspiration to have a pilot plant facility established at Hyderabad to develop, demonstrate and scale up innovative technologies relevant to the bulk drug industry and make these technologies accessible to Indian manufacturers, particularly MSMEs.

We strongly believe that collaboration between CSIR-NCL and BDMAI, supported by the Anusandhan National Research Foundation (ANRF), Government of India, would provide a valuable opportunity for the industry to adopt advanced manufacturing technologies, including continuous manufacturing, green chemistry and other sustainable process technologies. Access to such facilities would help manufacturers improve productivity, reduce manufacturing costs and environmental impact, and strengthen their competitiveness in international markets.

We are pleased to assure you that BDMAI will actively encourage its 220 member companies, of which about 80% are MSMEs, to utilise the proposed pilot plant facilities for process development, scale-up and validation across Technology Readiness Levels (TRL) 4 to 7, as envisaged under the initiative.

In view of Hyderabad's strong concentration of bulk drug and pharmaceutical manufacturing units, including a substantial number of MSMEs, we sincerely request you to consider Hyderabad as a location for establishing one of the proposed pilot plants. BDMAI would be pleased to provide a suitable grounding space in our technological development centre at Jeedimetla, Hyderabad and extend its cooperation in facilitating industry participation and utilisation of the proposed facilities.

We look forward to a positive consideration of our request.

Thanking you.

Yours sincerely,

BULK DRUG MANUFACTURERS ASSOCIATION Hyderabad

CH.A.P. Rameswara Rao
National President